A novel class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-independent locus
1999
New Cancer-Fighting Compounds
publication
Evidence: moderate
Author Information
Author(s): Skelton L A, Ormerod M G, Titley J, Kimbell R, Brunton L A, Jackman A L
Primary Institution: The CRC Centre for Cancer Therapeutics, The Institute of Cancer Research
Hypothesis
Can lipophilic quinazoline-based folic acid analogues serve as effective cytotoxic agents?
Conclusion
CB30865 is a potent anti-tumour agent with a novel mechanism of action.
Supporting Evidence
- CB30865 was the most potent growth inhibitory agent with IC50 values in the range of 1–100 nM.
- CB300179 and CB300189 were active in the micromolar range.
- CB30865 retained activity in the presence of exogenous thymidine.
- A cell line resistant to CB30865 was not cross-resistant to CB300179 or CB300189.
Takeaway
Scientists found a new type of medicine that can help fight cancer by working differently than other treatments.
Methodology
The study involved testing three compounds on various cell lines to measure their growth inhibitory effects.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website